文献库 文献相关信息

题目:
Clinical impact of predicting CCND1 amplification using plasma DNA in superficial esophageal squamous cell carcinoma.
作者:
Komatsu(Shuhei),Ichikawa(Daisuke),Hirajima(Shoji),Takeshita(Hiroki),Shiozaki(Atsushi),Fujiwara(Hitoshi),Kawaguchi(Tsutomu),Miyamae(Mahito),Konishi(Hirotaka),Kubota(Takeshi),Okamoto(Kazuma),Yagi(Nobuaki),Otsuji(Eigo)
状态:
发布时间2014-05-26 , 更新时间 2015-11-19
期刊:
Dig Dis Sci
摘要:
This study was designed to evaluate the clinical benefit of predicting the cyclin D1 (CCND1) status using cell-free plasma DNA in superficial esophageal squamous cell carcinoma (ESCC) patients.,The ratio of the CCND1 (11q13) dosage to the DRD2 (11q22-23) dosage (C/D ratio) as the CCND1 copy number was evaluated. This study was divided into three steps: (1) demonstration of the feasibility, (2) evaluation of whether the plasma C/D ratio assay could monitor tumor dynamics, and (3) a validation study in 63 consecutive superficial ESCC (pTis-T1) patients and 40 healthy volunteers.,(1) The plasma C/D ratio was significantly higher (p = 0.0369) in superficial ESCC patients than in the controls in a preliminary test. (2) The high plasma C/D ratio appeared to reflect the tumor levels of the CCND1 status and was reduced in postoperative plasma samples (p = 0.1154) and samples following endoscopic resection (p = 0.0845). (3) Validation analysis revealed that the plasma C/D ratio was significantly higher in superficial ESCC patients than in controls (p < 0.0001). The frequency of recurrence was significantly higher (p = 0.0198), and recurrence-free survival was significantly shorter (p = 0.0075) in patients with a high plasma C/D ratio. Moreover, a high C/D ratio was shown to be an independent risk factor for recurrence on multivariate analysis [p = 0.0334; odds ratio 10.58 (range 1.203-93.23)].,The prediction of CCND1 amplification by plasma DNA may be a new complementary clinical biomarker for recurrence in patients with superficial ESCC.
语言:
eng
DOI:
10.1007/s10620-013-3005-2

联系方式

山东省济南市 高新区 崇华路359号 三庆世纪财富中心C1115室

电话: 0531-88819269

E-mail: product@genelibs.com

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。